Many Investors Still Treating Gilead: 4 Launches This Year Could Prove Them Wrong
Gilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
Get essential year-end tax filing guidance for DRIP ETFs, including records to gather and strategies to reduce liabilities.
24,400 articlesGilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
This year, a familiar name in disruptive investing is turning heads as one of its picks climbs about 30%. Learn what ...
As markets swing and newcomers crowd the fintech scene, 2026 could determine whether Robinhood finally builds a durab...
Apple posted a record iPhone quarter and Meta pushed ad revenue higher, but each faces starkly different bets on AI a...
Figma stunned traders with a big Q1 2026 beat, lifting the stock on Friday morning. Here’s what happened, why it matt...
CoreWeave reported a $740 million quarterly loss as it stacked up a record backlog and a massive Meta deal, underscor...
With rates stabilizing in the mid-6% range, the housing market braces for a steadier second half of 2026. Pending sal...
In a volatile market, the dividend growth approach that emphasizes rising payouts over big yields is drawing attentio...
January data show a pending home sales fall, signaling continued headwinds for buyers even as rates move modestly low...
Winter is signaling a shift in the housing market. Demand is creeping back as buyers expect holiday discounts, while ...
Airbnb posts a solid Q4, prompting Truist to lift its target to $129 and move the stock to Hold. The shift signals a ...
A 64-year-old couple skipped a long-term care policy at 58 and now faces six-figure potential costs as health and ins...